Skip to main content
. Author manuscript; available in PMC: 2019 Jan 1.
Published in final edited form as: Antivir Ther. 2018;23(2):167–178. doi: 10.3851/IMP3194

Figure 1. Proportion of patients initiating in each drug class, by year of ART initiation.

Figure 1

(A) First-line regimen (drugs initiated in other drug class for first-line regimen included: raltegravir [0.4% overall]; clinical trial drug [<0.1%]). (B) Second-line regimen (drugs initiated in other drug class for second regimen included: raltegravir [3.9%]; clinical trial drug [1.8%]). (C) Third-line regimen (drugs initiated in other drug class for third regimen included: raltegravir [8.5%]; cobicistat [0.5%]; elvitegravir [0.5%]; clinical trial drug [3.8%]). NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; PI, protease inhibitor.